Galapagos creates new warrant plan
April 19 2018 - 4:02PM
Mechelen, Belgium; 19 April 2018, 22.01 CET; regulated
information -- Galapagos NV (Euronext & NASDAQ: GLPG)
announced today that its board of directors created
1,585,000 warrants under new warrant plans for the benefit of
employees, future employees, directors and a consultant of the
company and its subsidiaries.
On 19 April 2018, the board of directors of
Galapagos approved the "Warrant Plan 2018", a warrant plan intended
mainly for certain (future) employees of the company and its
subsidiaries, and also for directors and an independent consultant
of the company, and the "Warrant Plan 2018 RMV," a warrant plan
intended for certain employees of its French subsidiary, Galapagos
SASU, within the framework of the authorized capital. Under these
warrant plans, 1,585,000 warrants were created, subject to
acceptances, and offered to the beneficiaries of the plans.
The offer of warrants to directors remains
subject to approval of the annual shareholders' meeting to be held
on 24 April 2018.
The warrants have an exercise term of eight
years as of the date of the offer and have an exercise price of
€79.88 (the average closing price of the share on Euronext
Amsterdam and Brussels during the thirty days preceding the date of
the offer). The warrants are not transferable and can in principle
not be exercised prior to 1 January 2022. Each warrant gives the
right to subscribe to one new Galapagos share. Should the warrants
be exercised, Galapagos will apply for the listing of the resulting
new shares on a regulated stock market. The warrants as such will
not be listed on any stock market.
Galapagos' total share capital currently amounts
to €277,122,928.92; the total number of securities conferring
voting rights is 51,234,962, which is also the total number of
voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued
securities conferring voting rights is 3,660,623, which equals the
total number of voting rights that may result from the exercise of
these warrants, and excludes the 1,585,000 warrants of Warrant
Plan 2018 and Warrant Plan 2018 RMV, which were created
subject to acceptance. Galapagos does not have any convertible
bonds or shares without voting rights outstanding.
About GalapagosGalapagos (Euronext & NASDAQ: GLPG) is
a clinical-stage biotechnology company specialized in the discovery
and development of small molecule medicines with novel modes of
action. Galapagos' pipeline comprises Phase 3 through to discovery
programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis
and other indications. Our target discovery platform has delivered
three novel mechanisms showing promising patient results in,
respectively, inflammatory diseases, idiopathic pulmonary fibrosis
and atopic dermatitis. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service subsidiary
Fidelta, has approximately 600 employees, operating from its
Mechelen, Belgium headquarters and facilities in the Netherlands,
France, Switzerland, the United States and Croatia. More
information at www.glpg.com.
Investors:Elizabeth GoodwinVP IR &
Corporate Communications +1 781 460 1784
Paul van der HorstDirector IR & Business
Development +31 71 750 6707ir@glpg.com
Media:Evelyn FoxDirector Communications
+31 6 53 591 999 communications@glpg.com
Forward-looking statementsThis release
may contain forward-looking statements. Such forward-looking
statements are not guarantees of future results. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any forward-looking statements in this document, unless
specifically required by law or regulation.
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Apr 2023 to Apr 2024